毒性
急性毒性
药理学
医学
蛋白酵素
口腔
口服
纤溶
药物毒性
纤溶剂
生物利用度
化学
作者
Ragil Saptaningtyas,Sri Rejeki,Ana Hidayati Mukaromah,Amin Samiasih,Nanik Rahmani,Maya Dian Rakhmawatie,Stalis Norma Ethica
标识
DOI:10.1080/15376516.2026.2666608
摘要
The present study evaluated the acute oral toxicity profile of microencapsulated semi-purified fibrinolytic proteases derived from Bacillus tequilensis HSFI-5 (Indonesian Patent Application No. S00202313485) using a modified OECD Guideline 423–aligned fixed-dose parallel design. BALB/c mice (n = 50; equal sex distribution) received single oral doses of 50, 300, 2000, or 5000 mg/kg body weight and were monitored for 14 days for clinical signs, body weight progression, hematological indices, clinical biochemistry parameters, organ weights, and gross pathological changes. No mortality or treatment-related clinical abnormalities were observed at any dose level. Body weight gain remained progressive and comparable to controls. Hematological and biochemical parameters showed no consistent dose-dependent deviations indicative of systemic inflammatory, metabolic, hepatic, or renal dysfunction. Absolute and relative organ weights, including liver and kidneys, remained within physiological ranges, and necropsy revealed no macroscopic lesions. Based on OECD decision criteria, the median lethal dose (LD50) was estimated to exceed 5000 mg/kg body weight, indicating that the formulation is not classified for acute oral toxicity under the Globally Harmonized System. Collectively, these findings indicate no evidence of acute treatment-related toxicological effects under the conditions of this study. Interpretation is limited to single-dose exposure and should be confirmed by further investigations incorporating detailed histopathological and extended toxicity assessments.
科研通智能强力驱动
Strongly Powered by AbleSci AI